10x Genomics TXG Cash Flow Statement (2018-2026)

NASDAQ TXG
$62.65 -0.57 (-0.90%)
At close: Sep 4, 2026 · 4:00 PM EDT
Reported Financials

10x Genomics Quarterly Cash Flow Statement

Periods 32 quarters
Latest Jun 2026

10x Genomics reported cash from operations of $16.97M and free cash flow of $15.39M for the quarter ended Jun 2026, down 4.1% year over year. This cash flow statement covers 32 quarters of results from Sep 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-17.17M-18.45M-42.41M-64.46M-41.91M-17.21M-50.75M-62.41M-92.99M-48.95M-59.95M-37.90M-35.75M-49.03M-34.36M34.54M-27.47M-16.25M-13.47M-17.93M
Share-based CompensationStock Comp.
25.95M26.90M26.05M36.31M33.51M40.97M42.10M45.70M40.23M38.92M36.13M38.49M33.59M32.54M31.08M27.56M25.26M25.22M22.64M25.62M
Deferred Taxes
Asset Writedowns and ImpairmentWritedown
2.79M7.06M2.45M0.60M0.11M
Cash from OperationsCash from Ops.
-26.22M5.80M-20.80M-16.96M-9.56M13.72M-4.12M-11.53M-25.30M25.76M-15.72M7.50M21.64M-6.75M34.35M17.71M43.21M40.78M26.12M16.97M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
1.58M1.54M1.78M1.94M1.96M1.95M2.13M1.94M2.05M1.99M2.30M1.93M1.79M1.81M1.79M1.84M1.95M2.04M1.95M2.02M
Depreciation & Amortization (CF)Dep. & Amort.
5.70M5.78M6.19M6.50M6.16M6.52M6.48M9.94M9.37M9.72M9.19M8.97M8.96M8.75M8.02M7.82M10.30M10.06M9.96M9.66M
Change in Working Capital
Change in ReceivablesChange Receivables
19.39M6.83M-8.73M-0.30M7.35M20.62M-26.28M9.75M16.16M10.97M-23.52M-0.12M-7.68M4.37M-35.33M-2.59M-6.63M3.23M-7.98M8.51M
Change in InventoryChange Inventory
7.13M8.78M3.74M7.37M8.66M1.43M0.45M1.86M-2.57M-7.61M9.94M5.20M4.26M-9.62M-8.06M-7.03M-7.29M-5.58M-2.70M-3.00M
Change in Account PayablesChange Payables
2.48M-1.11M2.88M7.39M-4.18M-0.22M-0.78M2.10M-4.12M-3.21M4.58M1.12M4.34M-13.40M-2.55M6.04M-0.20M-5.42M4.78M3.29M
Change in Accured ExpensesChange Accured Exp.
18.40M4.47M-13.28M5.28M4.84M6.50M-15.13M4.82M19.47M19.15M-12.67M0.55M-5.01M4.40M-11.74M3.93M-2.12M17.59M-20.96M3.12M
Investing Activities
Capital ExpendituresCapex
20.23M27.62M28.14M27.22M36.57M39.73M30.67M-0.75M15.24M3.45M2.91M2.88M3.89M2.72M1.89M1.58M0.69M1.78M1.60M1.59M
Acquisitions
1.50M2.50M
Change in Acquisitions & DivestmentsChange Acquisitions
12.66M20.04M8.71M7.72M93.34M1.60M1.19M4.05M12.97M12.81M50.00M50.00M25.20M25.00M25.00M
Cash from Investing ActivitiesCash from Investing
-20.23M-27.62M-257.56M-27.53M-32.63M-33.17M119.96M-4.46M4.90M13.10M10.63M11.95M-3.62M-51.59M-1.89M-0.94M-8.80M-1.80M-1.31M-7.74M
Financing Activities
Other financing activitiesOther financing
6.68M8.90M7.83M6.36M2.04M5.00M5.81M3.68M4.37M5.61M1.64M4.60M0.16M4.52M0.42M3.52M0.62M2.24M0.27M3.02M
Cash from Financing ActivitiesCash from Financing
6.68M8.90M2.42M6.36M2.04M5.00M-3.41M7.10M4.37M5.61M1.64M4.60M0.16M4.52M0.42M3.52M0.62M2.24M-8.42M3.02M
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued
Additional items
Exchange Rate EffectFX Effect
0.12M-0.08M-0.02M-0.19M-0.09M0.25M0.02M-0.05M-0.09M0.08M-0.05M-0.00M0.16M-0.27M0.11M0.36M-0.03M0.04M-0.07M-0.03M
Change in Cash
-39.64M-12.99M-275.96M-38.32M-40.24M-14.20M112.44M-8.94M-16.11M44.55M-3.50M24.04M18.34M-54.09M32.99M20.65M35.00M41.26M16.32M12.23M
Free Cash FlowFCF
-46.44M-21.81M-48.94M-44.18M-46.14M-26.01M-34.79M-10.77M-40.54M22.31M-18.64M4.62M17.75M-9.46M32.46M16.13M42.53M39.00M24.52M15.39M
Net Cash FlowNCF
-39.76M-12.91M-275.94M-38.13M-40.16M-14.45M112.42M-8.89M-16.03M44.47M-3.46M24.05M18.18M-53.82M32.88M20.29M35.03M41.21M16.39M12.26M